 Connection
David Fox to Cell Line, Tumor
This is a "connection" page, showing publications David Fox has written about Cell Line, Tumor.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.163 |
|
|
|
-
Ruth JH, Gurrea-Rubio M, Athukorala KS, Rasmussen SM, Weber DP, Randon PM, Gedert RJ, Lind ME, Amin MA, Campbell PL, Tsou PS, Mao-Draayer Y, Wu Q, Lanigan TM, Keshamouni VG, Singer NG, Lin F, Fox DA. CD6 is a target for cancer immunotherapy. JCI Insight. 2021 03 08; 6(5).
Score: 0.095
-
Parameswaran N, Luo L, Zhang L, Chen J, DiFilippo FP, Androjna C, Fox DA, Ondrejka SL, Hsi ED, Jagadeesh D, Lindner DJ, Lin F. CD6-targeted antibody-drug conjugate as a new therapeutic agent for T cell lymphoma. Leukemia. 2023 10; 37(10):2050-2057.
Score: 0.028
-
Du Y, Lu C, Morgan RL, Stinson WA, Campbell PL, Cealey E, Fu W, Lepore NJ, Hervoso JL, Cui H, Urquhart AG, Lawton JN, Chung KC, Fox DA, Amin MA. Angiogenic and Arthritogenic Properties of the Soluble Form of CD13. J Immunol. 2019 07 15; 203(2):360-369.
Score: 0.021
-
Enyindah-Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, Moasser MM, Wang B, Singer NG, Cui H, Ohara RA, Rasmussen SM, Fox DA, Lin F. CD318 is a ligand for CD6. Proc Natl Acad Sci U S A. 2017 08 15; 114(33):E6912-E6921.
Score: 0.019
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|